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Objectives: To evaluate community-based health workers’ ability to identify cases of hypertension in pregnancy,
safely deliver methyldopa and magnesium sulphate and make referrals when appropriate.
Study design: This was part of Nigeria Community-Level Interventions for Pre-eclampsia (CLIP) cluster ran
domized controlled trial (NCT01911494). Community-based Health Workers (CHW) recruited pregnant women
from five Local Government Areas (clusters) and used mobile health aid for clinical assessment of pre-eclampsia.
Main outcome measures: The primary outcome was the number of adverse events that occurred after the
administration of magnesium sulphate and/or methyldopa to pregnant women by CHWs.
Findings: Of 8790 women receiving mobile health-guided care, community-based health workers in Nigeria
provided 309 women with hypertension (4.2% of delivered women), and safely administered 142 doses of
intramuscular magnesium sulphate. Community Heath Extension Workers (CHEWs) and nurses gave fifty-two
and sixty-seven doses of intramuscular magnesium sulphate respectively, twenty-three doses were given by
other health care workers (midwives, community health officers, health assistants). The high rate of adminis
tration by nurses can be explained by turf protection as well as their seniority within the health system. Also,
CHEWs and nurses gave 124 doses of oral methyldopa and 126 urgent referrals were completed. There were no
complications related to administration of treatment or referral.
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Interpretation: These findings demonstrate the ability of community-based health workers to safely administer
methyldopa and intramuscular magnesium sulphate. The use of task-sharing, therefore, could drastically reduce
the three delays (triage, transport and treatment) associated with high maternal mortality and morbidity in rural
communities in low- and middle-income countries.

1. Introduction

2.2. Clinical intervention

Nigeria has one of the highest maternal mortality ratios (MMR) in the
world with an estimated 814 maternal deaths per 100 000 live births in
2015 [1]. In the same year, India and Nigeria were responsible for over
one third of all maternal deaths worldwide. Pregnancy hypertension is
common and its incidence in south-western Nigeria was found to be as
high as 10.2 [2]. Pre-eclampsia, and its complications, often occur in
rural communities where there are inadequate resources available for
emergency obstetric care [3–5]. The appropriate management of preeclampsia, which is typically available only in hospital settings, in
volves supportive care with frequent maternal and foetal surveillance,
anti-hypertensives, seizure prophylaxis, and timely delivery [6–11].
Magnesium sulphate (MgSO4) is the anticonvulsant of choice and is
presently included in Nigeria’s essential medicines list as the first line
drug in the management of pre-eclampsia and eclampsia [12,13]. Ten
centres in Nigeria participated in the 1995 multicentre Collaborative
Eclampsia Trial where magnesium was proven to be effective in the
treatment of eclampsia, despite this, its use in the country remains
limited [13,14]. Some barriers to the adoption of MgSO4 are poor
dissemination of international guidelines, insufficient health worker
training, the perceived need for intensive patient monitoring, stock outs
and a lack of adequate manpower [14–16].
Many low- and middle-income countries (LMIC) utilize task-sharing
to optimize the delivery of key effective maternal and newborn in
terventions [17]. This involves delegating responsibilities previously
reserved for highly trained health workers to existing or new cadres of
health workers with either less or narrowly tailored training [18,19].
These health workers can be useful in bridging the gap between re
cipients and providers and thus, reduce delays [17]. In Nigeria,
community-based health workers are the first point of contact in the
health system and provide a range of services in the home and at primary
health centres (PHC). There is evidence to suggest that trained
community-based health workers had good understanding of the fea
tures of pre-eclampsia, could identify women at risk, and initiate care
[20].
The Community Level Interventions for Pre-eclampsia (CLIP) study
employed task-sharing to community-based health workers in Nigeria to
identify and provide emergency treatment for pre-eclampsia prior to
referral. This paper aims to assess the ability of community-based health
workers to safely initiate lifesaving therapies (MgSO4 and methyldopa)
for women with pre-eclampsia with the aid of an mHealth decision-aid,
at primary health centres in Ogun State, Nigeria.

The Community-based Health Workers (CHW), who implemented
the CLIP study, were nurses, midwives, community health extension
workers (CHEW), and health assistants (HAs), all of whom normally
provide care at the community-level in Nigeria. The implementation
itself involved clinical assessment of pregnant woman based on de
mographics, symptoms and signs to identify likely cases of hypertensive
disorders of pregnancy (HDP) and if the condition was severe, initiate
treatment and referral. This process was guided by a mobile health
application, PIERS on the Move (POM) [22]. The POM treatment algo
rithm was based on the miniPIERS (Pre-eclampsia Integrated Estimate of
RiSk) model that was predictive of adverse maternal outcome and
perinatal death among women with HDPs in LMIC [22]. In brief, there
were seven CLIP ‘triggers’ for action that resulted in recommendations
to administer 750 mg oral methyldopa (for severe hypertension), 10 mg
intramuscular MgSO4 (for presumed pre-eclampsia), and attend the
nearest comprehensive emergency obstetric care (CEmOC) facility ur
gently (for women with severe complications such as stroke) or 24 h (for
non-severe hypertension). Successful use of this mobile application by
minimally trained community-based health workers has previously been
demonstrated [23].
A two-day training was provided for community-based health
workers, at conveniently-located health centres, with refresher trainings
provided every six months. Each community-based health worker was
provided a transport allowance to encourage participation. Training
facilitators were consultant obstetricians, medical officers, and nurses.
Strategies used for training included didactic lectures, group work, case
studies, role play, and practical demonstrations; importantly, pre- and
post-tests were administered, and direct observations undertaken, to
ensure that community-based health workers trained had adequate
knowledge and skills. A ‘train-the-trainer’ model was used, where lead
community-based health workers would train others in the facility who
were not present on the initial day of training. In the training sessions,
community-based health workers were provided information on: (i) the
HDPs, focussing on the warning symptoms and signs of pre-eclampsia
with the aid of pictograms; (ii) measurement of blood pressure at
antenatal and postnatal visits using a low-cost, simple-to-use, semiautomated handheld blood pressure device validated for use in preeclampsia [24,25] (i.e., the Microlife 3AS1-2 and then the Microlife
Vital Sign Alert (VSA) after January 23, 2015); (iii) dipstick measure
ment of proteinuria, (iv) entry of basic demographic and pregnancy
information into an electronic platform; (v) how to follow recommen
dations provided by POM; (vi) administration of oral methyldopa and/
or intramuscular MgSO4, and (vi) counselling women about the need for
referral [23].
This training supplemented health workers’ professional qualifica
tions. Nurses had completed a three-year program at various nursing
schools throughout Nigeria, and midwives completed an additional year
and half maternity-focused training. CHEWs hold a Diploma in com
munity health, having completed a three-year program, primarily at
Schools of Health Technology. The CHEW curriculum is focused on
community diagnosis and treatment of minor ailments and diseases in
preparation for community outreach and assistance at PHCs, including
monitoring of labour and delivery; only a few classes in the CHEW
curriculum relate to the HDPs. The skills acquired include history taking,
physical examination, vital sign monitoring, and administration of oral
medications and intramuscular injections. Some nurses and CHEWs had
also completed an additional one-year advanced course in primary

2. Methods
2.1. Study setting
This study was conducted in Ogun State, Nigeria from March 01,
2014 to January 31, 2016. Ogun State is populated mainly by the Yoruba
ethnic group, roughly 50% of the population live in rural areas, and are
served by a mix of public and private health care facilities. Of Ogun
State’s twenty Local Government Areas (LGAs), ten were chosen for
participation in the CLIP cluster randomized controlled trial
(NCT01911494) [21]. Five of the ten LGAs were randomly chosen as
intervention clusters (i.e. Remo North, Ogun Waterside, Odeda, Ijebu
Northeast, and Yewa South), and within each cluster, five to seven wards
were selected on the basis of ease of access into the community given the
large size of the clusters.
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health to become community health officers (CHO) (n = 11). HAs are a
lower cadre of community-based health workers whose skill set is more
limited, consisting of taking vital signs, collecting preliminary clinical
and pregnancy history.

Table 1
Number of visits per pregnancy.
Total
pregnancies
(N = 8790)
mean (sd)/n
(%)

2.3. Study participants and data collection
All women aged 15–49 years, who resided in the study area, and
were identified as pregnant during routine antenatal care at a public
PHC were eligible for participation in the CLIP trial. All eligible women
who gave verbal and written consent were included in the study.
Community-based health care workers used the POM application on a
mobile android device to collect demographic information and record
blood pressure, proteinuria, and other PIERS parameters data during
routine antenatal clinics.

Total visits*
Visits per pregnancy

2.4. Ethical approval

Pregnancies with ≥ 4 antenatal visits
(% of total pregnancies with antenatal visits)
Pregnancies with a visit every 4 weeks
(% of total pregnancies with at least two visits and expected to
have delivered by end of trial Jan 09, 2016)
Total number of postpartum visits
(% of total visits)
Pregnancies with at least one postpartum visit
(% of total pregnancies with at least two visits and expected to
have delivered by end of trial Jan 09, 2016 (7016))
Postpartum visits per pregnancy
(for all those with postpartum visits (2416))
Postpartum visits per pregnancy
(for all those expected to be postpartum by the end of the trial)
Pregnancies with ≥ 4 antenatal visits and at least one postpartum
visit
(for all those expected to be postpartum by the end of the trial)

Reach
Total number of antenatal visits
(% of all visits)
Pregnancies with at least one antenatal visit
(% of all pregnancies)
Fidelity
Antenatal visits per pregnancy

Ethical approval for this study was obtained from the Health
Research and Ethics Committee of Olabisi Onabanjo University Teach
ing Hospital, Sagamu, Nigeria (as the in-country co-ordinating centre)
and the Clinical Research Ethics Board of the University of British
Columbia, Vancouver, Canada (as the central co-ordinating site) (H1203497). All women and community-based health workers provided
written informed consent for participation prior to enrolment.
2.5. Outcomes
This piece of process evaluation addressed the fidelity (how closely
health workers followed the protocol and intervention as intended e.g.
adherence to the recommended schedule of antenatal visits: 4-weekly
during pregnancy until 28 weeks, fortnightly from 28 to 35 weeks and
weekly thereafter, within 24 h of birth, and on approximately days 3, 7,
and 14 after delivery), dose (how much of the clinical intervention was
delivered), and reach (the number of recipients of the intervention) of
the CLIP intervention [26].

32 703
3⋅7
[± 2⋅8]
25 745
(78⋅7%)
8680
(98⋅7%)
3⋅0
[± 2⋅2]
2693
(31⋅0%)
1721
(24.5%)
6956
(21⋅3%)
2416
(34.4%)
2⋅9
[± 1⋅2]
1⋅0
[± 1⋅6]
1043
(14⋅9%)

*
All visits in this analysis include, at a minimum, completed blood pressure mea
surements or emergency condition(s).

these visits were antepartum (78.7%); however, 27.5% of pregnancies
received at least one postpartum visit. Few women (30.6%) received
four or more antenatal visits, and even fewer received the newly rec
ommended eight visits (4.7%).

2.6. Statistical analysis

3.1. Community-level treatment of pre-eclampsia with MgSO4 and
methyldopa

The aim of this analysis was to describe the ability of communitybased health workers to administer life-saving emergency therapy in
the study area from March 01, 2014 to January 31, 2016. Ability is
assessed by the following proxies: acceptance rates and number of
adverse events related to treatment. Means and standard deviations are
presented for continuous variables.

The total number of study visits at PHCs with MgSO4 recommended
was 154 (0⋅5% of total visits), 139 visits recommended methyldopa
(0⋅4% of total visits), all whom also received MgSO4. The vast majority
of these pregnancies were recommended treatment as a result of severe
systolic hypertension (an average systolic blood pressure ≥ 160 mmHg):
85⋅7% of visits with a recommendation for MgSO4 and 89⋅9% of visits
with a recommendation for methyldopa (Table 2). All women who were
provided treatment were also recommended referral within four hours
to the nearest CEmOC facility.

2.7. Role of the funding source
The funder had no role in designing the study, data collection and
analysis, the decision to publish, or the preparation of this manuscript.
The corresponding author had full access to all the data in the study and
final responsibility for the decision to submit for publication.

3.2. Acceptance of MgSO4 and methyldopa treatment

3. Results

Out of the 139 visits with methyldopa recommended, 124 (89⋅2%)
accepted this treatment. Similarly, there was a high rate of acceptance
for MgSO4, of the 154 MgSO4 recommendations, 136 (88⋅3%) accepted.
Seventy-four percent (n = 127) of those recommended urgent referral,
within four hours, accepted (Table 3). The most common reason for
refusal of transport was permissions not obtained from husband or de
cision-maker (n = 17.52% of refusal responses). In the study period, 67
(49⋅3%) visits resulted in administration of MgSO4 by nurses, 52
(38⋅2%) by CHEWs, 21 by midwives (15⋅4%), 1 (0⋅7%) by CHO and a HA
provided MgSO4 on only one occasion (0⋅7%).

In the 29 participating wards in five clusters, 170 (57.8%)
community-based health workers were trained: 83 (48.8%) CHEWs, 14
(8⋅2%) HAs, and 73 (42⋅9%) nurses. Twenty-five of the nurses had
additional qualification as midwives. The most common reason why
community-based health workers were not trained were personnel lo
gistics at the health facility, unwillingness to take up additional re
sponsibility, and turf protection among nurses and lower cadre health
workers.
These community-based health workers enrolled 8790 pregnant
women (Table 1) during routine antenatal care at public PHCs. These
women received an average of three visits per pregnancy, the majority of
181
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Table 2
MgSO4 and methyldopa treatment recommendations.

Table 4
Adverse events related to community treatment with MgSO4, methyldopa, and
referral.

Total visits with MgSO4
recommended
(N = 154)
Total visits with a miniPIERS risk ≥ 25%*
Visits with a miniPIERS risk ≥ 25%* that
triggered treatment
Total visits with severe systolic hypertension

†

Total visits with severe diastolic hypertension

†

Visits with severe diastolic hypertension that
triggered treatment†,‡
Total visits with signs of recent seizure reported
Total visits with signs of recent seizure confirmed
Total visits with signs of recent stroke reported
Total visits that reported ¥vaginal bleeding +
non-severe systolic hypertension

Severe systolic hypertension
Total visits with severe diastolic hypertension†

Visits with MgSO4 administered
(N = 136)

5
(3⋅2%)
5
(3⋅2%)
132
(85⋅7%)
76
(49⋅4%)
55
(35⋅7%)
9
(5⋅8%)
0
(0%)
0
(0%)
0
(0%)

Follow-up visits after treatment with MgSO4
Visits with MgSO4 and an adverse event
Visits with a hematoma
Visits with an infection at injection site

Total visits with methyldopa
recommended
(N ¼ 139)
125
(89⋅9%)
71
(50⋅1%)
50
(36⋅0%)

In the CLIP Trial, community-based health workers were able to use
the POM application to recognize women at risk of pre-eclampsia and
eclampsia and to provide appropriate treatment and referral.
There is considerable evidence regarding the treatment of preeclampsia and eclampsia by nurses, whereas the literature is far more
limited regarding lay community-based health workers. There is a
general consensus that it is within the scope of nurses and midwives to
administer antihypertensives for severe hypertension in pregnancy;
however, WHO did not recommend this task be performed by
community-based health workers [17]. WHO has also recommended
that nurses administer a loading dose of MgSO4 for prevention and
treatment of eclampsia prior to referral [17]. It is important to note that
this is recommended in the context of targeted monitoring and evalua
tion. Studies carried out in Nigeria have demonstrated the ability of
trained community-based health workers to triage and initiate preeclampsia treatment [27,28]. This has led to a change in national pol
icy such that community-based health workers are authorized to
administer a loading dose of MgSO4 before referral [28]. Although some
studies have suggested that community-based health workers in LMIC
could be employed to provide timely care to women with pre-eclampsia,
there is currently no existing systematic review on the treatment of preeclampsia and eclampsia by community-based health workers [29]. A
systematic review of tested dosing regimens of magnesium sulphate for
managing pre-eclampsia and eclampsia demonstrated the necessity for
further studies to determine if a MgSO4 loading dose could be safely
administered in the community [30].
Pubmed was searched for relevant literature with the following key
words: “community health workers”, “preeclampsia”, “eclampsia”,
“magnesium sulphate”, “low- and middle-income countries”.
To our knowledge, this is the first study in a LMIC to assess the ability
of community-based health workers to initiate life saving therapies for
pre-eclampsia with the assistance of an mHealth platform. Similar
studies that examined the ability of CHEWs to provide MgSO4 in Nigeria
did not include use of mHealth [27,28]. Moreover, the ability of the
community-based health workers to safely administer antihypertensives

Antepartum bleeding of a spoonful or greater.
A miniPIERS score is determined by a predictive model for adverse outcome in
pregnant/postpartum women with hypertension, a score of ≥25% indicates a likeli
hood of adverse outcome of ≥25%.
‡
Diastolic blood pressure was a trigger for treatment only after January 23, 2015.
*

Table 3
Acceptance of MgSO4 and methyldopa.

Visits with MgSO4 recommended

154
(0⋅5%)
Visits with methyldopa recommended 139
(0⋅4%)
Visits with four-hour referral
171
recommended
(0⋅5%)

136
(88⋅3%)
124
(89⋅2%)
126
(73⋅7%)

16
(10⋅%4)
12
(8⋅6%)
41
(24⋅0%)

Visits with injury reported during this
referral
Visits with injury confirmed during this
referral

Visits with four-hour referral
accepted
(N ¼ 126)
0
(0%)
0
(0%)

4. Discussion

¥

Total
Accepted Refused
(N = 32 703)

Follow-up visits after treatment with
methyldopa

Visits with methyldopa
administered
(N ¼ 124)
79
(58⋅1%)

or the first 42 days postpartum by a community-based health worker.
Fifty-eight percent (n = 79) of women who received methyldopa had a
subsequent visit at some point by a community-based health worker.

Visits with severe diastolic hypertension that
triggered treatment†,‡
Triggers are not mutually exclusive.
Severe systolic hypertension is defined as an average systolic blood pressure ≥160.†
Non-severe systolic hypertension is defined as average systolic blood pressure ≥140.
Severe diastolic hypertension is defined as average diastolic blood pressure ≥110.†
After December 18th, 2015 MgSO4 was not recommended for any women known to
be prior to 20 weeks gestation.

Dose

89
(65⋅4%)
0
(0%)
0
(0%)
0
(0%)

Missing
2
(1⋅3%)
3
(2⋅2%)
4
(2⋅3%)

3.3. The safety of community-level administration of MgSO4,
methyldopa, and referral
There were no adverse events related to the administration of MgSO4
or methyldopa in the study period. There was one injury in transport to a
CEmOC facility, after thorough review of this case, it was confirmed that
the woman suffered a minor injury to her arm due to seizures during
transport in a poorly maintained vehicle; therefore, the injury was un
likely related to the community management of pre-eclampsia. There
were no cases of serious unexpected events related to any of the treat
ments provided. In addition, there were no reported instances of
mistreatment or overtreatment resulting in magnesium toxicity. There
were also no reports of infection or hematoma at injection sites
(Table 4). Sixty-five percent (n = 89) of pregnancies with MgSO4
administered received a subsequent visit at some time during pregnancy
182
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was not assessed in previous studies.

4.2. Limitations of the study

4.1. Implications of all the available evidence

This study did not measure outcomes such as the reduction of
maternal mortality.
The CLIP intervention did not reduce adverse pregnancy outcomes in
the CLIP trials in India, Pakistan and Mozambique (adjusted OR 1⋅17,
95% CI 0⋅90–1⋅51; p = 0⋅24) [33–36]. The CLIP trial was initiated in
Ogun State, Nigeria on 1 March 2015, and closed on 31 January 2016.
Considerable logistical challenges in data-entry from paper forms to
electronic database for the surveillance process led to the difficult de
cision to halt the clinical research trial. The data gathered by the way of
the mobile device was of high quality and integrity. This was done by
mutual consent with the local research team and under the aegis of the
local and institutional research and ethics board.
Fetal outcomes were not available for women who received treat
ment and/or referral as part of the CLIP trial, therefore, we cannot
extrapolate the perinatal impact of these interventions. In addition, data
regarding respiratory depression were not collected following treatment
with MgSO4, nevertheless, existing evidence indicates this is not a grave
concern with an occurrence of only 1.3% [37].

The findings from the CLIP study in Nigeria are far-reaching and
could improve the health of pregnant women with pre-eclampsia. Tasksharing of emergency lifesaving treatments with the aid of mHealth may
contribute to a significant reduction in maternal morbidity and
mortality.
In this study, women deemed to be at-risk were provided evidencebased treatment and referred by community-based health workers.
There were no adverse events associated with this treatment. There was
high level of acceptance among women who were recommended
methyldopa (89⋅2%) for severe hypertension. The rate of acceptance for
MgSO4 was similarly high (88⋅3%), despite the invasive nature of
intramuscular treatment. These results suggest that community pro
viders, if properly trained, can safely and appropriately administer
MgSO4 and methyldopa to women with pre-eclampsia. These findings
support previous studies that demonstrated the ability of minimally
trained health workers to safely administer MgSO4 [27,28]. The ability
of community-based health workers to safely initiate emergency treat
ment at primary health centres could lead to a reduction of morbidity
and mortality associated with the hypertensive disorders of pregnancy.
In a study conducted in five PHCs in Kano State, community-based
health workers were trained to detect severe pre-eclampsia/eclampsia,
administer 10 mg of MgSO4 intramuscularly, treat any serious MgSO4related reactions with calcium gluconate, and refer to facilities for
ongoing management. Among women with severe pre-eclampsia/
eclampsia, more from study PHCs failed to attend facilities for
ongoing care (90%) compared with those in control PHCs (56%) [26].
No adverse outcomes or toxicity was reported in association with PHCadministration of MgSO4 in the study [27]. In the CLIP study, 73.7% of
the women accepted recommendation for referral which may suggest a
higher acceptance of referral compared with the previous study con
ducted in Kano State. This difference may be the consequence of
extensive targeted training of health workers [19]. Additionally, health
care providers resided in the communities in which they worked; this
may have contributed to the higher level of adherence to recommen
dations and a higher rate of follow-up post-treatment as they are trusted
members of their communities. This high rate of follow-up indicates an
ability to ensure safety and efficacy beyond immediate treatment at the
community-level.
This study illustrates the potential benefits to be gained through
appropriate and careful task-sharing for maternal health interventions.
Further evidence regarding effectiveness is required before the admin
istration of MgSO4 and oral antihypertensives by lay health workers is
included in international guidelines, such as WHO’s recommendations
for optimizing health workers’ roles to improve access to key maternal
and newborn health interventions [17].
Community-based health workers can serve as a bridge to the health
facility in resource constrained settings. This study has shown that when
properly trained, these providers can make appropriate decisions
regarding treatment and referral of women with pre-eclampsia. Early
detection, through regular high-quality antenatal care [31], and the
provision of lifesaving therapies at the community-level may reduce
maternal and perinatal morbidities and mortalities associated with preeclampsia. It is important to note that there may be cases of turf pro
tection among the community-based health workers- some nurses and
midwives may feel that CHEWs and other lower CHWs should not be
empowered to ‘treat’ obstetric cases such as pre-eclampsia [19].
The CLIP trials in India, Pakistan and Mozambique were not a costeffective approach to reducing adverse maternal and perinatal out
comes as implemented; however, when women received at least eight
home-based visits from community-based health workers, there was a
cost-effective reduction in a composite of maternal and perinatal mor
tality and morbidity, driven primarily by perinatal mortality [32].

5. Conclusion
These findings confirm the ability of community-based health
workers to safely administer methyldopa and intramuscular magnesium
sulphate. The use of task-sharing, therefore, could reduce the three de
lays (triage, transport and treatment) associated with high maternal
mortality and morbidity in rural communities in low- and middleincome countries. There is a need for further studies among
community-based health workers in other similar settings. A systematic
review of these studies may thus justify this as an international
recommendation.
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